JP2010501572A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501572A5
JP2010501572A5 JP2009525631A JP2009525631A JP2010501572A5 JP 2010501572 A5 JP2010501572 A5 JP 2010501572A5 JP 2009525631 A JP2009525631 A JP 2009525631A JP 2009525631 A JP2009525631 A JP 2009525631A JP 2010501572 A5 JP2010501572 A5 JP 2010501572A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
deuterium
formulation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525631A
Other languages
English (en)
Other versions
JP2010501572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/018655 external-priority patent/WO2008024439A2/en
Publication of JP2010501572A publication Critical patent/JP2010501572A/ja
Publication of JP2010501572A5 publication Critical patent/JP2010501572A5/ja
Pending legal-status Critical Current

Links

Claims (11)

  1. 式Iaの化合物、
    Figure 2010501572
    (式中、各Yは独立して水素および重水素から選択され、少なくとも1つのYは重水素であり、共通の炭素原子に結合された各Yは同じである)
    またはその塩あるいはその水和物または溶媒和物。
  2. 1a、Y1bおよびY1cが、同時に重水素である、請求項1に記載の化合物。
  3. 2aおよびY2bが、同時に重水素である、請求項1または請求項に記載の化合物。
  4. 3aおよびY3bが、同時に重水素である、請求項1から請求項のいずれか1項に記載の化合物。
  5. 4aおよびY4bが、同時に重水素である、請求項1から請求項のいずれか1項に記載の化合物。
  6. 5aおよびY5bが、同時に重水素である、請求項1から請求項のいずれか1項に記載の化合物。
  7. 以下の表に記載する化合物のうちのいずれか1つから選択された、請求項1に記載の化合物、
    Figure 2010501572
    または、前記化合物のいずれか1つのトシレート塩。
  8. 重水素として指定されない任意の原子が、その天然の同位体存在量で存在する、請求項1から請求項のいずれか1項に記載の化合物。
  9. 請求項1に記載の化合物と、許容できる担体とを含む、発熱物質を含まない組成物であって、前記組成物は薬理学的な投与のために処方されており、前記担体は薬理学的に許容できる担体である、発熱物質を含まない組成物
  10. 癌、食道腺癌、食道扁平上皮癌、子宮頚癌、頭頚部癌、固形腫瘍、非ホジキンリンパ腫、胃癌、卵巣癌、腹膜癌、脳腫瘍および中枢神経系癌(神経膠腫、多形神経膠芽腫、膠肉腫)、前立腺癌、子宮内膜癌、結腸直腸癌、非小細胞肺癌、肝癌、腎癌、および膵癌を患っているか、またはこれらを起こしやすい状態にある被験体を治療するための製剤であって、請求項9に記載の組成物を含む製剤
  11. 前記被験体が乳癌を患っているか、またはこれらを起こしやすい状態にある、請求項10に記載の製剤
JP2009525631A 2006-08-22 2007-08-22 4−アミノキナゾリン誘導体およびその使用方法 Pending JP2010501572A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83950306P 2006-08-22 2006-08-22
PCT/US2007/018655 WO2008024439A2 (en) 2006-08-22 2007-08-22 4-aminoquinazoline derivatives and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2010501572A JP2010501572A (ja) 2010-01-21
JP2010501572A5 true JP2010501572A5 (ja) 2010-09-30

Family

ID=39107412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525631A Pending JP2010501572A (ja) 2006-08-22 2007-08-22 4−アミノキナゾリン誘導体およびその使用方法

Country Status (9)

Country Link
US (2) US20080051422A1 (ja)
EP (1) EP2054063A4 (ja)
JP (1) JP2010501572A (ja)
KR (1) KR20090042994A (ja)
CN (1) CN101594870A (ja)
AU (1) AU2007288204A1 (ja)
CA (1) CA2661223A1 (ja)
MX (1) MX2009001814A (ja)
WO (1) WO2008024439A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Crth2アンタゴニストとしての同位体富化されたピリミジン−5−イル酢酸誘導体
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
CN101735200B (zh) * 2008-11-17 2013-01-02 岑均达 喹唑啉类化合物
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CN102453025B (zh) * 2010-10-18 2014-08-13 齐鲁制药有限公司 拉帕替尼中间体晶型及其制备方法
EP2654754B1 (en) * 2010-12-17 2016-12-21 Novartis AG Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
CN102321076B (zh) * 2011-07-07 2013-08-21 中国科学技术大学 拉帕替尼中间体及其类似物的制备方法
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN102911164A (zh) * 2012-11-07 2013-02-06 江苏金桥盐化集团利海化工有限公司 一种拉帕替尼关键中间体的制备方法
ITVI20130003A1 (it) * 2013-01-14 2014-07-14 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di lapatinib e suoi sali mediante nuovi intermedi.
US9024023B2 (en) 2013-01-14 2015-05-05 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
CN104513231A (zh) * 2015-01-09 2015-04-15 安润医药科技(苏州)有限公司 拉帕替尼及其中间体的合成方法
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
AU2018341454B2 (en) * 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
CN107827877B (zh) * 2017-11-21 2021-05-07 陕西师范大学 二烷基氨基喹唑啉类化合物及其在制备抗肿瘤药物中的应用
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN108187055B (zh) * 2018-03-06 2019-12-27 北京大学 一种具有协同增效作用的抗癌组合物
CN108690001A (zh) * 2018-06-26 2018-10-23 苏州市贝克生物科技有限公司 拉帕替尼类似物的合成

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2534405A1 (en) * 2003-08-08 2005-02-17 Ulysses Pharmaceutical Products Inc. Halogenated quinazolinyl nitrofurans as antibacterial agents
WO2005046678A1 (en) * 2003-11-07 2005-05-26 Smithkline Beecham (Cork) Limited Cancer treatment method
MXPA06013635A (es) * 2004-06-03 2007-02-28 Smithkline Beecam Cork Ltd Metodo para el tratamiento de cancer.
WO2005120512A2 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
EP2277595A3 (en) * 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
WO2010005585A2 (en) * 2008-07-09 2010-01-14 Concert Pharmaceuticals Inc. 4-aminoquinazoline prodrugs

Similar Documents

Publication Publication Date Title
JP2010501572A5 (ja)
JP2017537080A5 (ja)
JP2022017295A5 (ja)
JP2012082227A5 (ja)
JP2019516766A5 (ja)
JP2012153722A5 (ja)
JP2016538344A5 (ja)
NZ561609A (en) 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
PH12017501989A1 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
JP2014513704A5 (ja)
NZ587504A (en) Benzopyrazole derivatives as ERK inhibitors
JP2013512263A5 (ja)
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
JP2022071077A5 (ja)
JP2008505167A5 (ja)
JP2017036314A5 (ja)
WO2017044858A3 (en) Inhibitors of cyclin-dependent kinases
IL266563B (en) Heterocyclic compounds used as pdk1 inhibitors
MX2009011343A (es) Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas.
JP2010523670A5 (ja)
JP2013166763A5 (ja)
JP2017526662A5 (ja)
JP2016503414A5 (ja)
MX2014013367A (es) Composiciones organicas para tratar enfermedades relacionadas con kras.